Corrigendum

Mathilde Bonnet*, Marine Dermu, Clara Roessle, Marc Bellaiche, Tarik Abarou, Véronique Vasseur, Samira Benakouche and Thomas Storme

Corrigendum to: Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method

<https://doi.org/10.1515/pthp-2018-9005>

Corrigendum to: Mathilde Bonnet, Marine Dermu, Clara Roessle, Marc Bellaiche, Tarik Abarou, Véronique Vasseur, Samira Benakouche and Thomas Storme. Formulation of a 3-months Stability Oral Viscous Budesonide Gel and Development of an Indicating Stability HPLC Method. *Pharmaceutical Technology in Hospital Pharmacy*. Volume 3, Issue 2, pages 91–99. (DOI <https://doi.org/10.1515/pthp-2018-0005>)

In Table 1, on page 94, the formulation was based on the original formula published by Eyal Zur, compounding pharmacist and consultant from Israel, in the *International Journal of Pharmaceutical Compounding* in 2012. [1]

[1] Zur, E. 2012. Eosinophilic esophagitis: treatment with oral viscous budesonide. *Int. J. Pharm. Compd.* 16: 288–293.

***Corresponding author: Mathilde Bonnet**, Pharmacy, Hôpital Universitaire Robert-Debre, 48 boulevard Sérurier, Paris 75019, France, E-mail: mathildb@hotmail.fr

Marine Dermu, Pharmacy, Hôpital Universitaire Robert-Debre, 48 boulevard Sérurier, Paris 75019, France

Clara Roessle, Pharmacy, Hôpital Universitaire Robert-Debre, 48 boulevard Sérurier, Paris 75019, France

Marc Bellaiche, Gastroenterology, Hôpital Universitaire Robert-Debre, Paris, Île-de-France, France

Tarik Abarou, Véronique Vasseur, Samira Benakouche, Thomas Storme, Pharmacy, Hôpital Universitaire Robert-Debre, 48 boulevard Sérurier, Paris 75019, France